Zobrazeno 1 - 10
of 528
pro vyhledávání: '"59"'
Autor:
Fritz Offner, Karima Amaador, Kazem Nasserinejad, Dries Deeren, Efstathios Kastritis, Steven T. Pals, Willem Kraan, Jeanette K. Doorduijn, Roberto D Liu, Monique C. Minnema, Marcel Kap, Marie José Kersten, Lara H Böhmer, Lidwine W. Tick, Meletios A. Dimopoulos, Josephine M.I. Vos, Martine E D Chamuleau, Maria Gavriatopoulou
Publikováno v:
JOURNAL OF CLINICAL ONCOLOGY
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 40(1), 40-51. American Society of Clinical Oncology
Kersten, M J, Amaador, K, Minnema, M C, Vos, J M I, Nasserinejad, K, Kap, M, Kastritis, E, Gavriatopoulou, M, Kraan, W, Chamuleau, M E D, Deeren, D, Tick, L W, Doorduijn, J K, Offner, F, Böhmer, L H, Liu, R D, Pals, S T & Dimopoulos, M A 2022, ' Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia : Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 40, no. 1, pp. 40-51 . https://doi.org/10.1200/JCO.21.00105
Journal of clinical oncology, 40(1), 40-51. American Society of Clinical Oncology
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 40(1), 40-51. American Society of Clinical Oncology
Kersten, M J, Amaador, K, Minnema, M C, Vos, J M I, Nasserinejad, K, Kap, M, Kastritis, E, Gavriatopoulou, M, Kraan, W, Chamuleau, M E D, Deeren, D, Tick, L W, Doorduijn, J K, Offner, F, Böhmer, L H, Liu, R D, Pals, S T & Dimopoulos, M A 2022, ' Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia : Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 40, no. 1, pp. 40-51 . https://doi.org/10.1200/JCO.21.00105
Journal of clinical oncology, 40(1), 40-51. American Society of Clinical Oncology
PURPOSE Proteasome inhibitors are effective in Waldenström's macroglobulinemia (WM) but require parenteral administration and are associated with polyneuropathy. We investigated efficacy and toxicity of the less neurotoxic oral proteasome inhibitor
Autor:
Ruey-Long Hong, Jia-Hong Chen, Ching Yun Hsieh, Li Yuan Bai, Chen Yuan Lin, Ming-Yu Lien, Mu-Hsin Chang, Shang-Hung Chen, Ren-Hua Ye, Muh Hwa Yang, Nai-Jung Chiang, Shang-Yin Wu, Chin-Fu Hsiao, Hsiang-Fong Kao, Li-Tzong Chen, Tsang Wu Liu
Publikováno v:
Journal of Clinical Oncology. 39:6025-6025
6025 Background: Liposomal irinotecan (nal-IRI) + 5-FU/LV has been approved and used in treating patients with metastatic pancreatic cancer after gemcitabine-based therapy through the NAPOLI-1 study result. This phase 2 trial evaluated the activity o
Publikováno v:
Journal of Clinical Oncology. 38:79-79
79 Background: Nivolumab (NIVO) plus ipilimumab (IPI) is a commonly used therapy for advanced melanoma. Original weight-based dosing of NIVO 1 mg/kg plus IPI 3 mg/kg (NIVO1+IPI3) was approved in 2017. Recently, the CHECKMATE 511 trial demonstrated im
Autor:
Ivana Gojo, Leo Luznik, B. Douglas Smith, Shannon R. McCurdy, Ephraim J. Fuchs, William Matsui, Douglas E. Gladstone, Margaret M. Showel, Yvette L. Kasamon, Hua Ling Tsai, Lode J. Swinnen, Michael A. McDevitt, Gabrielle T. Prince, Gary L. Rosner, Keith W. Pratz, Richard J. Jones, Amy E. DeZern, Jennifer A. Kanakry, Richard F. Ambinder, Mark J. Levis, Karlo Perica, Satish Shanbhag, Javier Bolaños-Meade, Ivan Borrello, Robert A. Brodsky, Carol Ann Huff
Publikováno v:
Journal of Clinical Oncology. 33:3152-3161
Purpose Recent advances in nonmyeloablative (NMA), related HLA-haploidentical blood or marrow transplantation (haplo-BMT) have expanded the donor pool. This study evaluated the effect of age on NMA haplo-BMT outcomes in patients age 50 to 75 years. P
Autor:
Carla Boquimpani, Tomasz Sacha, Franck E. Nicolini, Naoto Takahashi, Sandip Acharya, Jeffrey H. Lipton, Beatriz Moiraghi, Jolanta Dengler, Dong-Wook Kim, Nelma Cristina D. Clementino, Raquel De Paz Arias, Noam Benyamini, Catherine Bouard, Rafik Fellague-Chebra, Timothy P. Hughes, Francois-Xavier Mahon, Vasily Shuvaev, Anna G. Turkina
Publikováno v:
Journal of Clinical Oncology. 37:7005-7005
7005 Background: In the ENESTop study (NCT01698905) of TFR in pts with CML-CP who achieved a sustained deep molecular response (MR) with 2L NIL, 57.9% remained in TFR 48 wks after stopping NIL (primary endpoint). Analyses at 144 wks showed durability
Autor:
Sharon Forsyth, Michael Roughton, Krystyna Reczko, Michael Baum, Allan Hackshaw, Richard Sainsbury, Kathryn Monson
Publikováno v:
Journal of Clinical Oncology. 29:1657-1663
Purpose The Cancer Research UK “Over 50s” trial compared 5 and 2 years of tamoxifen in women with early breast cancer. Results are reported after median follow-up of 10 years. Patients and Methods Between 1987 and 1997, 3,449 patients age 50 to 8
Autor:
Marcia Hall, Michael Muschol, Miguel Angel Climent, Martine Piccart-Gebhart, S. Muehlbauer, Walter Tsang Wu Liu, Marion Procter, Veerle Van Dooren, Urania Dafni, Evandro de Azambuja, Jorge Madrid, R. Charles Coombes, Christian Focan, Masakazu Toi, Olivia Pagani, Thomas M. Suter, Shin-Cheh Chen, Ernst Rechberger, Dirk J. van Veldhuisen, David Dodwell
Publikováno v:
Journal of Clinical Oncology, 28(21), 3422-3428. AMER SOC CLINICAL ONCOLOGY
Purpose We investigated the incidence of cardiac adverse events in patients with early breast cancer in the Herceptin Adjuvant (HERA) trial who were treated with 1 year of trastuzumab after completion of (neo)adjuvant chemotherapy. Patients and Metho
Autor:
Jose Carlos Martinez Avila, Jair Tenorio, Hoi Tong, Lorena Ostios, Nuria Rodriguez Salas, Alberto M. Borobia, María Teresa García Morales, Jesus Miranda, Mario Muñoz, Gema Gordo
Publikováno v:
Journal of Clinical Oncology. 36:718-718
718 Background: mCRC is the 2º cause of death in the world. Development of targeted therapies has increased the survival. The efficacy of these drugs (such Bevacizumab and monoclonal antibodies against EGFR) depends on the use of genetic biomarkers
Autor:
Marisol Urbieta, Eric Leblanc, Paul Cottu, Elisabeth Chereau, Christophe Pomel, Romain Rouzier, Sebastien Gouy, Sarah Zohar, Julien Dupin, Leila Kockler, Sabine Balouet, Florence Joly, Eric Lambaudie, Rose-Marie Ferri, Anne Floquet, Frédéric Selle
Publikováno v:
Journal of Clinical Oncology. 35:5538-5538
5538 Background: ANTHALYA showed that neoadjuvant Bevacizumab (B) added to Carboplatin and Paclitaxel (CP) was well tolerated and achieved encouraging complete resection rates at IDS (58.6%) in unresectable FIGO stage IIIC/IV ovarian, tubal or perito
Autor:
Yee Soo Chae, Joohyuk Sohn, Keun-Seok Lee, Kyung-Hun Lee, Kyung Hae Jung, Ki Hyeong Lee, Ji-Yeon Kim, Soo Jung Lee, Jin-Hee Ahn, In Hae Park, Gun Min Kim, Tae Yong Kim, Seock-Ah Im, Jee Hyun Kim, Yeon Hee Park, Se Hyun Kim, Hye Sook Han, Sung-Bae Kim, Young-Hyuck Im
Publikováno v:
Journal of Clinical Oncology. 35:1082-1082
1082 Background: PG chemotherapy is one of the preferred chemotherapeutic regimens for patients with MBC. Eribulin mesylate is a non-taxane inhibitor of microtubule dynamics of the halichondrin class. A recent pooled analysis with eribulin showed imp